Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Vismodegib
Drug ID BADD_D02365
Description Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Indications and Usage Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Marketing Status approved; investigational
ATC Code L01XJ01
DrugBank ID DB08828
KEGG ID D09992
MeSH ID C538724
PubChem ID 24776445
TTD Drug ID D03EDQ
NDC Product Code 50242-140
UNII 25X868M3DS
Synonyms HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616
Chemical Information
Molecular Formula C19H14Cl2N2O3S
CAS Registry Number 879085-55-9
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract obstruction20.08.01.0040.000112%
Disease progression08.01.03.0380.002574%
Disease recurrence08.01.03.0500.000739%Not Available
Drug intolerance08.06.01.013--Not Available
Neoplasm recurrence16.16.02.0040.000437%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000112%Not Available
Investigation13.18.01.004--Not Available
Metastasis16.22.01.0010.000112%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000660%Not Available
Adverse reaction08.06.01.0180.000381%Not Available
Cholestatic liver injury09.01.07.0160.000112%Not Available
Diffuse alopecia23.02.02.0070.000246%Not Available
Myeloproliferative neoplasm16.21.03.006; 01.13.03.0060.000112%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000246%Not Available
Recurrent cancer16.16.01.015--Not Available
Ruptured cerebral aneurysm24.02.04.005; 17.08.01.0590.000112%Not Available
Poor dental condition07.09.05.0140.000246%Not Available
Metastases to nervous system17.02.10.022; 16.22.02.0190.000112%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000168%Not Available
Trichodysplasia spinulosa23.03.08.015; 10.03.02.0040.000112%Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.0130.000112%Not Available
Foreign body reaction23.03.15.012; 08.01.05.0160.000381%Not Available
Illness08.01.03.091--Not Available
Myelosuppression01.03.03.0150.000168%Not Available
Skin neoplasm bleeding24.07.01.104; 23.08.02.014; 16.03.02.0140.000168%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.004555%Not Available
Therapy non-responder08.06.01.0630.001802%Not Available
Therapy partial responder08.06.01.0640.000761%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.067--Not Available
The 7th Page    First    Pre   7    Total 7 Pages